共 80 条
[1]
Vogelstein B(2013)Cancer genome landscapes Science 339 1546-1558
[2]
Papadopoulos N(2011)Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 245-255
[3]
Velculescu VE(2012)Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study Br J Cancer 106 1722-1727
[4]
Wilhelm SM(2013)Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 303-312
[5]
Dumas J(2013)Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 295-302
[6]
Adnane L(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 389 56-66
[7]
Strumberg D(2012)Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial Lancet Oncol 13 1055-1062
[8]
Scheulen ME(2012)A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors Clin Cancer Res 18 2658-2667
[9]
Schultheis B(2012)Regorafenib for cancer Expert Opin Investig Drugs 21 879-889
[10]
Grothey A(2012)Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial J Clin Oncol 30 2401-2407